Brad Screnci
About Brad Screnci
Brad Screnci is a Product Manager and Business Development Associate at Integral Molecular, where he has worked since 2021. He also serves as an Adjunct Professor at Rowan College at Burlington County and has a diverse background in research and finance.
Current Role at Integral Molecular
Brad Screnci currently serves as a Product Manager and Business Development Associate at Integral Molecular, a position he has held since 2021. In this role, he focuses on managing the growth of an antibody discovery platform, which enables partners to accelerate the discovery and development of therapeutics targeting membrane proteins. He has successfully managed multiple antibody discovery campaigns against challenging membrane protein targets, leading to intellectual property filings and a licensing partnership.
Previous Experience at University of Pennsylvania
Before joining Integral Molecular, Brad Screnci worked as a Research Specialist at the University of Pennsylvania for four months in 2016. His role contributed to research initiatives in the Greater Philadelphia Area, enhancing his expertise in scientific research and development.
Academic Background
Brad Screnci has a diverse educational background. He earned a Bachelor's degree from Rutgers University in Communication, Information & Library Studies, completing his studies from 1997 to 2001. He later pursued a Master's degree in Bioscience Technologies at Thomas Jefferson University, which he completed in 2014. Additionally, he has served as an Adjunct Professor at Rowan College at Burlington County since 2016, where he shares his knowledge and experience with students.
Career Progression and Previous Roles
Brad Screnci has held various positions in the mortgage and biopharmaceutical industries. He worked as an Account Executive at Ownit Mortgage Solutions and BNC Mortgage, as well as a Collateral Risk Analyst and Credit Risk Specialist at PHH Mortgage. His experience also includes a role as an Associate Scientist at Aro Biotherapeutics, where he supported the development of a therapeutic candidate pipeline based on alternative scaffold proteins called Centyrins.
Research Contributions and Initiatives
During his tenure at Integral Molecular, Brad Screnci has made significant contributions to the field of antibody discovery. He managed multiple campaigns that addressed complex membrane protein targets, resulting in intellectual property advancements and partnerships. His work has been pivotal in enhancing the capabilities of the antibody discovery platform, facilitating the development of new therapeutic options.